Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
  • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
  • C07K16/1036—Retroviridae, e.g. leukemia viruses
  • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/46—Hybrid immunoglobulins
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/46—Hybrid immunoglobulins
  • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
  • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
  • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
  • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
  • C07K2317/626—Diabody or triabody
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
  • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

• Blinatumomab a BiTE® targeting CD19
• BLINCYTOTM Philadelphia chromosome-negative relapsed/refractory B-acute lymphoblastic leukemia under the trade name BLINCYTOTM.
• the BiTE® platform is one of the clinically most advanced T-cell immunotherapy options.
• scTCRs are produced as a single polypeptide, avoiding the requirement for production of each TCR chain as separate polypeptides and allowing for production of larger quantities of the properly assembled scTCR that binds to its peptide-MHC ligand. This feature can allow for production yields that are necessary for clinical use.
• scTCRs consisting of only the V regions (scTv) can be formatted as therapeutics or diagnostic reagents similar to scFv fragments.
• the diabody molecules further comprise an Fc region, which is disclosed herein as it allows engineering of antibody-like properties (e.g. long half-life) into the molecule.
• EP1868650 requires the presence of binding regions of light chain or heavy chain variable domains of an immunoglobulin, and extensively discusses functional Fc receptor binders.
• Other objects and advantages of the present invention will become apparent when studying the following description and the preferred embodiments thereof, as well as the respective examples.
• variable domain (VR1 ) of a TCR specifically binding to an MHC-associated peptide epitope
• the second polypeptide chain comprises a second binding region of a variable domain (VR2) of a TCR specifically binding to an MHC-associated peptide epitope, and a second binding region of a variable domain (VD2) of an antibody specifically binding to a cell surface antigen of a human immune effector cell, and
• VR2 variable domain
• VD2 variable domain
• first binding region (VD1 ) and said second binding region (VD2) associate to form a first binding site (VD1 )(VD2) that binds the epitope of the cell surface molecule;
• said two polypeptide chains are fused to human IgG hinge domains and/or human IgG Fc domains or dimerizing portions thereof;
• inventive dual specificity polypeptide molecules according to the present invention are exemplified here by a dual specificity polypeptide molecule comprising a first polypeptide chain comprising SEQ ID No. 16 and a second polypeptide chain comprising SEQ ID No. 17.
• the invention relates to the dual specificity polypeptide molecule according to the invention, the nucleic acid or the expression vector(s) according to the invention, the cell according to the invention, or the pharmaceutical composition according to the invention, for use in the treatment of a disease or disorder as disclosed herein, in particular selected from cancer and infectious diseases.
• the dual specificity polypeptide molecule according to the present invention comprise a first polypeptide and a second polypeptide chain providing a first (VD1 ) and a second (VD2) binding region, respectively, of a variable domain derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells.
• This first binding region (VD1 ) and said second binding region (VD2) associate to form a first binding site (VD1 )(VD2) that binds the epitope of the immune effector cell surface antigen.
• first and the second polypeptide chain of the polypeptide molecule comprises a first (VR1 ) and a second (VR2) binding region, respectively, of a variable domain derived from a TCR being specific for an MHC-associated peptide epitope.
• Said first binding region (VR1 ) and said second binding region (VR2) associate to form a second binding site (VR1 )(VR2) that binds said MHC-associated peptide epitope.
• the FcTv-cellular receptor e.g. CD3
• scTv-cellular receptor e.g. CD3
• FC region in the first polypeptide chain comprises SEQ ID No. 26 (Fc1 )
• FC region in the second polypeptide chain comprises SEQ ID No. 27 (Fc2).
• exemplary dual specificity polypeptide molecule comprising a first polypeptide chain comprising SEQ ID No. 16 (1 . chain of full molecule) and a second polypeptide chain comprising SEQ ID No. 17 (2. chain of full molecule).
• binding sites (VD1 )(VD2) and (VR1 )(VR2) of the present description preferably specifically bind to a surface antigen of human immune cells and a peptide-HLA molecule complex, respectively.
• "specific binding” and grammatical variants thereof are used to mean a site having a binding affinity (KD) for a peptide-HLA molecule complex and/or an antibody epitope of 100 ⁇ or less.
• the disclosure further provides for aspects wherein the percent identity of at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% applies to any of the sequences of the structural regions described in Figure 1 , for example, VD1 , VR1 , Linkl , VR2, VD2, Link2, or hinge region, and as described or being part of the sequences as disclosed herein.
• VD1 may have at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to the amino acid sequence of SEQ ID NO: 28.
• LINK1 or LINK2 may have at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to the amino acid sequence of SEQ ID NO: 30.
• VD2 may have at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to the amino acid sequence of SEQ ID NO: 31 .
• VR2 may have at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to the amino acid sequence of SEQ ID NO: 32.
• agents include cis-platin, maytansine derivatives, rachelmycin, calicheamicin, docetaxel, etoposide, gemcitabine, ifosfamide, irinotecan, melphalan, mitoxantrone, sorfimer sodiumphotofrin II, temozolomide, topotecan, trimetreate glucuronate, auristatin E vincristine and doxorubicin; peptide cytotoxins, i.e. proteins or fragments thereof with the ability to kill mammalian cells.
• Figure 3 shows the HPLC-SEC analysis of different bispecific TCR/mAb molecules with a molecular design according to the constructs depicted in Figure 2, which were purified by a 2-column purification process.
• the monomer contents of the different molecules were determined as follows. II: 93.84%; III: 96.54%; IV: 98.49%; IA_1 : 95.48%; IA_3: 98.45%; ID_1 : 95.75%; IC_4: 95.22%; IC_5: 92.76%; ID_4: 99.31 %; ID_5: 99.44%.
• Figure 6 shows the results of the potency assay conducted with different lgG1 - based bispecific TCR/mAb constructs (as shown in Figure 2) utilizing different variable antibody domains both targeting the TCR-CD3 complex.
• Construct ID_1 comprises variable domains of the UCHT1 (V9) antibody targeting CD3, whereas the constructs ID_4 and ID_5 comprise variable domains of the alpha/beta TCR-specific antibody BMA031 .
• Jurkat_NFATRE_luc2 cells were co-incubated with HIV-peptide SLYNTVATL (SEQ ID No. 7) loaded T2 cells in the presence of increasing concentrations of bispecific TCR (bssTCR) molecules.
• Figure 1 1 shows the results of a LDH-release assay with the bispecific TCR/mAb diabody construct IA_5 targeting tumor-associated peptide PRAME- 004 (SEQ ID No. 49) presented on HLA-A * 02.
• CD8-positive T cells isolated from a healthy donor were co-incubated with cancer cell lines UACC-257, SW982 and U2OS presenting differing amounts of PRAME-004:HLA-A * 02-1 complexes on the cell surface (approx. 1 100, approx. 770 and approx. 240 copies per cell, respectively, as determined by M/S analysis) at an effector:target ratio of 5:1 in the presence of increasing concentrations of TCR/mAb diabody molecules.
• After 48 hours of co-culture target cell lysis was quantified utilizing LDH-release assays according to the manufacturer's instructions (Promega).
• Figure 12 shows the results of a LDH-release assay with the bispecific TCR/mAb diabody constructs IA_5 and IA_6 utilizing a stability/affinity maturated TCR and an enhanced version thereof, respectively, against the tumor-associated peptide PRAME-004 (SEQ ID No. 49) presented on HLA- A * 02.
• CD8-positive T cells isolated from a healthy donor were co-incubated with the cancer cell line U2OS presenting approx. 240 copies per cell of PRAME- 004 :HLA-A * 02-1 complexes or non-loaded T2 cells (effector:target ratio of 5:1 ) in the presence of increasing concentrations of TCR/mAb diabody molecules.
• After 48 hours of coculture target cell lysis was quantified utilizing LDH-release assays according to the manufacturer's instructions (Promega).
• IA-lgG4 868Z11 hUCHT1(V9) SEQ ID No.8 lgG4 (KiH)
• IA_1 868Z11 hUCHT1(V9) SEQ ID No. lgG1 (K/O, KiH)
• IC_4 868Z11 hBMA031(var10) SEQ ID No. lgG1 (K/O, KiH- 18 ds)
• IC_5 868Z11 hBMA031(var10) SEQ ID No. lgG1 (K/O, KiH- 20 ds) extended
• Bispecific molecules were purified using an Akta Pure 25 L FPLC system (GE Lifesciences) equipped to perform affinity and size-exclusion chromatography in line. Affinity chromatography was performed on protein A columns (GE Lifesciences) following standard affinity chromatographic protocols. Size exclusion chromatography was performed directly after elution (pH 2.8) from the affinity column to obtain highly pure monomeric protein using Superdex 200 pg 16/600 columns (GE Lifesciences) following standard protocols. Protein concentrations were determined on a NanoDrop system (Thermo Scientific) using calculated extinction coefficients according to predicted protein sequences. Concentration, if needed, and buffer exchange was performed using Vivaspin devices (Sartorius). Finally, purified molecules were stored in phosphate-buffered saline at concentrations of about 1 mg/mL at temperatures of 2-8°C.
• T cell Activation Bioassay Promega.
• the assay consists of a genetically engineered Jurkat cell line that expresses a luciferase reporter driven by an NFAT-response element (NFAT-RE). Assays were performed according to the manufacturer. Briefly, T2 cells either loaded with the HIV-specific peptide SLYNTVATL (SEQ ID No.
• the potency assay results revealed target-dependent Jurkat reporter T cell activation and minimal unspecific activity against unloaded T2 cells for both antibody variable domains hUCHTI (construct ID_1 ) and hBMA031 (constructs ID_4 and ID_5) supporting the platform suitability of the dual specificity TCR/mAb diabody constructs (Figure 6).
• hUCHTI construct ID_1
• hBMA031 constructs ID_4 and ID_5
• Figure 6 shows that when the variable TCR and mAb domains of the constructs ID_4 and ID_5 were switched on each polypeptide chain resulting in constructs IC_4 and IC_5 no T cell activation was observed (data not shown).
• IC_4 and IC_5 no T cell activation was observed (data not shown).
• the latter finding indicate that despite bispecific TCR/mAb diabodies can be used as platform construct for incorporating different TCR and mAb variable domains a thorough optimization of the domain orientation is required to achieve optimal activity of the
• the protein construct were further subjected to heat-stress at 40°C for up to two weeks to analyze stability of the PRAME-004-specific TCR/mAb diabody variants IA_5 and IA_6.
• HPLC-SEC analyses after heat-stress revealed a significantly improved stability of the variant IA_6 when compared to the precursor construct IA_5 (see Figure 13).
• the temperature-induced increase of high-molecular species (i.e. eluting before the main peak) of the constructs was less pronounced for IA_6 than for IA_5.
• the recovery of intact, monomeric protein after heat-stress was 87% and 92% for IA_5 and IA_6, respectively.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Medicinal Chemistry (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Virology (AREA)
• AIDS & HIV (AREA)
• Oncology (AREA)
• Hematology (AREA)
• Cell Biology (AREA)
• Peptides Or Proteins (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (13)

Applications Claiming Priority (10)

Publications (1)

Family

ID=62951983

Family Applications (2)

Family Applications After (1)

Country Status (28)

Cited By (22)

Families Citing this family (28)

Citations (34)

Family Cites Families (71)

• 2018
  • 2018-07-13 LT LTEP18740829.9T patent/LT3652215T/lt unknown
  • 2018-07-13 WO PCT/EP2018/069151 patent/WO2019012138A1/en not_active Ceased
  • 2018-07-13 DK DK18740829.9T patent/DK3652215T3/da active
  • 2018-07-13 EP EP21191794.3A patent/EP3985029A1/en active Pending
  • 2018-07-13 EP EP18183508.3A patent/EP3428194B1/en active Active
  • 2018-07-13 AU AU2018298884A patent/AU2018298884A1/en not_active Abandoned
  • 2018-07-13 SG SG11202000025SA patent/SG11202000025SA/en unknown
  • 2018-07-13 DK DK18183508.3T patent/DK3428194T3/da active
  • 2018-07-13 RS RS20210561A patent/RS61817B1/sr unknown
  • 2018-07-13 KR KR1020207004221A patent/KR20200026995A/ko not_active Ceased
  • 2018-07-13 US US16/035,403 patent/US11905328B2/en active Active
  • 2018-07-13 US US16/035,412 patent/US20190016802A1/en not_active Abandoned
  • 2018-07-13 MD MDE20190844T patent/MD3428194T2/ro unknown
  • 2018-07-13 US US16/035,420 patent/US20190016803A1/en not_active Abandoned
  • 2018-07-13 PT PT181835083T patent/PT3428194T/pt unknown
  • 2018-07-13 PL PL18740829T patent/PL3652215T3/pl unknown
  • 2018-07-13 PE PE2020000058A patent/PE20200615A1/es unknown
  • 2018-07-13 WO PCT/EP2018/069157 patent/WO2019012141A1/en not_active Ceased
  • 2018-07-13 JP JP2020501174A patent/JP2020530762A/ja active Pending
  • 2018-07-13 CN CN201880046726.5A patent/CN110914308A/zh active Pending
  • 2018-07-13 HU HUE18183508A patent/HUE057110T2/hu unknown
  • 2018-07-13 AU AU2018298881A patent/AU2018298881B2/en active Active
  • 2018-07-13 US US16/035,429 patent/US20190016804A1/en not_active Abandoned
  • 2018-07-13 ES ES18183508T patent/ES2898210T3/es active Active
  • 2018-07-13 HU HUE18740829A patent/HUE054568T2/hu unknown
  • 2018-07-13 MA MA46299A patent/MA46299B1/fr unknown
  • 2018-07-13 CA CA3069842A patent/CA3069842A1/en active Pending
  • 2018-07-13 MD MDE20200533T patent/MD3652215T2/ro unknown
  • 2018-07-13 CR CR20200013A patent/CR20200013A/es unknown
  • 2018-07-13 ES ES18740829T patent/ES2871146T3/es active Active
  • 2018-07-13 RS RS20211381A patent/RS62544B1/sr unknown
  • 2018-07-13 SI SI201830456T patent/SI3428194T1/sl unknown
  • 2018-07-13 KR KR1020207004219A patent/KR102833184B1/ko active Active
  • 2018-07-13 SI SI201830285T patent/SI3652215T1/sl unknown
  • 2018-07-13 BR BR112020000769-2A patent/BR112020000769A2/pt not_active Application Discontinuation
  • 2018-07-13 PL PL18183508T patent/PL3428194T3/pl unknown
  • 2018-07-13 PT PT187408299T patent/PT3652215T/pt unknown
  • 2018-07-13 CA CA3069610A patent/CA3069610A1/en active Pending
  • 2018-07-13 EP EP18740829.9A patent/EP3652215B1/en active Active
  • 2018-07-13 BR BR112020000762-5A patent/BR112020000762A2/pt unknown
  • 2018-07-13 CR CR20200014A patent/CR20200014A/es unknown
  • 2018-07-13 LT LTEP18183508.3T patent/LT3428194T/lt unknown
  • 2018-07-13 CN CN201880046721.2A patent/CN110914307A/zh active Pending
  • 2018-07-13 HR HRP20211744TT patent/HRP20211744T1/hr unknown
  • 2018-07-13 SG SG11202000027WA patent/SG11202000027WA/en unknown
  • 2018-07-13 PE PE2020000056A patent/PE20200614A1/es unknown
  • 2018-07-16 TW TW107124492A patent/TWI762677B/zh not_active IP Right Cessation
  • 2018-07-16 TW TW110149543A patent/TWI817302B/zh not_active IP Right Cessation
  • 2018-07-17 JP JP2018134424A patent/JP6784724B2/ja active Active
• 2020
  • 2020-01-14 MX MX2020011744A patent/MX2020011744A/es unknown
  • 2020-01-28 CO CONC2020/0001029A patent/CO2020001029A2/es unknown
  • 2020-02-10 ZA ZA2020/00842A patent/ZA202000842B/en unknown
  • 2020-02-11 CO CONC2020/0001491A patent/CO2020001491A2/es unknown
• 2021
  • 2021-05-06 CY CY20211100387T patent/CY1124091T1/el unknown
  • 2021-11-01 CY CY20211100934T patent/CY1124835T1/el unknown
• 2022
  • 2022-03-03 US US17/686,358 patent/US20220185888A1/en not_active Abandoned
  • 2022-03-12 US US17/693,323 patent/US20220195044A1/en not_active Abandoned
• 2023
  • 2023-05-22 JP JP2023083663A patent/JP2023103451A/ja active Pending
  • 2023-06-08 US US18/331,556 patent/US20230348598A1/en active Pending
  • 2023-11-24 JP JP2023198791A patent/JP2024023385A/ja active Pending
• 2025
  • 2025-06-17 US US19/240,392 patent/US20250361300A1/en active Pending

Patent Citations (44)

Non-Patent Citations (38)

Also Published As

Similar Documents

Legal Events